Hikal Ltd Stock Falls to 52-Week Low Amidst Continued Downtrend

Stock Price Movement and Market Context

On 1 February 2026, Hikal Ltd’s stock recorded an intraday low of Rs 189, closing with a day’s loss of 2.25%. This underperformance was more pronounced relative to its sector, as the Pharmaceuticals & Biotechnology segment outpaced the stock by 2.08% on the same day. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.

The broader market environment also reflected volatility, with the Sensex opening 119.19 points higher but subsequently reversing sharply to close down by 1.3% at 81,196.37 points. The Sensex itself is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating mixed signals for market breadth.

Long-Term Performance and Relative Comparison

Over the past year, Hikal Ltd’s stock has delivered a negative return of 45.68%, significantly lagging behind the Sensex’s positive 5.78% gain during the same period. The stock’s 52-week high was Rs 456.6, underscoring the steep decline it has experienced. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the last three years, one year, and three months.

Financial Metrics and Profitability Trends

Hikal Ltd’s financial fundamentals have shown signs of deterioration over recent years. The company’s operating profits have contracted at a compound annual growth rate (CAGR) of -16.24% over the last five years, indicating weakening earnings capacity. This decline is further reflected in the company’s earnings per share (EPS), which fell sharply by 320.54% in the September 2025 quarter, resulting in very negative quarterly results.

Profit after tax (PAT) for the latest quarter stood at a loss of Rs 34.90 crore, marking a 320.5% decline compared to the previous four-quarter average. Return on capital employed (ROCE) for the half-year period was recorded at a low 4.44%, while the operating profit to interest coverage ratio for the quarter dropped to 0.48 times, highlighting challenges in meeting interest obligations from operating earnings.

Debt and Capital Structure Considerations

The company’s debt servicing ability remains constrained, with a high Debt to EBITDA ratio of 2.51 times. This elevated leverage ratio suggests a relatively high burden of debt relative to earnings before interest, taxes, depreciation, and amortisation. Meanwhile, the average return on equity (ROE) has been modest at 8.00%, indicating limited profitability generated per unit of shareholders’ funds.

Valuation and Relative Discount

Despite the subdued financial performance, Hikal Ltd’s valuation metrics present a contrasting picture. The stock trades at an enterprise value to capital employed ratio of 1.6, which is considered attractive relative to its peers. This valuation discount reflects the market’s cautious stance given the company’s recent results and outlook. Over the past year, profits have declined by 86.2%, reinforcing the subdued earnings environment.

Shareholding and Market Grade

The majority shareholding in Hikal Ltd remains with the promoters, maintaining a stable ownership structure. However, the company’s overall market capitalisation grade is rated at 3, reflecting its mid-tier market cap status. The company’s Mojo Score currently stands at 12.0, with a Mojo Grade of Strong Sell, an upgrade from the previous Sell rating as of 14 November 2025, signalling continued caution from rating agencies.

Summary of Recent Performance and Market Position

Hikal Ltd’s stock has experienced a sustained decline over the past year, culminating in its recent touch of the 52-week low near Rs 189. The stock’s underperformance relative to the Sensex and its sector peers reflects a combination of weak earnings growth, declining profitability, and elevated leverage. The company’s financial ratios, including ROCE and interest coverage, remain subdued, while the negative quarterly results have contributed to the cautious market sentiment.

While the stock’s valuation metrics suggest a discount relative to peers, the overall market grade and Mojo Score indicate a strong sell stance, underscoring the challenges faced by the company in reversing its downtrend. The promoter holding remains intact, but the company’s ability to improve profitability and capital efficiency will be critical in shaping future market perceptions.

Market and Sector Outlook

The Pharmaceuticals & Biotechnology sector continues to exhibit mixed performance, with some companies outperforming while others face headwinds. Hikal Ltd’s recent price action and financial results place it among the underperformers within the sector. The broader market volatility, as seen in the Sensex’s sharp reversal on 1 February 2026, adds to the challenging environment for stocks with weaker fundamentals.

Conclusion

Hikal Ltd’s fall to its 52-week low is a reflection of ongoing pressures on its financial health and market valuation. The stock’s performance over the last year, combined with deteriorating profitability metrics and elevated debt levels, has contributed to its current market position. While valuation discounts exist, the company’s recent results and financial ratios continue to weigh on investor sentiment, as reflected in the strong sell rating and Mojo Score.

Unlock special upgrade rates for a limited period. Start Saving Now →